United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 6.5mmol) effervescent tablets bpc 1968 (actavis uk ltd - potassium bicarbonate; potassium acid tartrate - effervescent tablet - 500mg ; 300mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 13.3mmol/5ml) solution for infusion 5ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 27mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 200mg/1ml

United States - English - NLM (National Library of Medicine)

american health packaging - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium chloride 750 mg - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. - for the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. - for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, (e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrhea

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 13.3mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 100mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/10ml) solution for infusion 10ml ampoules (martindale pharmaceuticals ltd - potassium chloride - solution for infusion - 150mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 10mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 1.5mg/1ml ; 9mg/1ml

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

potassium 20mmol/500ml) / sodium chloride 0.9% infusion 500ml viaflo bags (baxter healthcare ltd - potassium chloride; sodium chloride - infusion - 3mg/1ml ; 9mg/1ml

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi limited - potassium chloride - concentrate for soln for inf - 15 %w/v - potassium chloride

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - potassium cation 20 meq - because of reports of intestinal and gastric ulceration and bleeding with controlled-release potassium chloride preparations, these drugs should be reserved for those patients who cannot tolerate or refuse to take liquid or effervescent potassium preparations or for patients in whom there is a problem of compliance with these preparations. 1.    for the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. if hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2.    for the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, eg, digitalized patients or patients with significant cardiac arrhythmias. the use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patie